IS7601A - Neisser-bóluefnasamsetningar sem innihalda blönduaf mótefnavökvum - Google Patents

Neisser-bóluefnasamsetningar sem innihalda blönduaf mótefnavökvum

Info

Publication number
IS7601A
IS7601A IS7601A IS7601A IS7601A IS 7601 A IS7601 A IS 7601A IS 7601 A IS7601 A IS 7601A IS 7601 A IS7601 A IS 7601A IS 7601 A IS7601 A IS 7601A
Authority
IS
Iceland
Prior art keywords
neisser
antibodies
antigens
compositions containing
vaccine compositions
Prior art date
Application number
IS7601A
Other languages
English (en)
Inventor
Jacques Berthet Francois-Xavier
Biemans Ralph
Denoel Philippe
Feron Christiane
Goraj Carine
Poolman Jan
Weynants Vincent
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31722002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7601(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0218035A external-priority patent/GB0218035D0/en
Priority claimed from GB0218036A external-priority patent/GB0218036D0/en
Priority claimed from GB0218051A external-priority patent/GB0218051D0/en
Priority claimed from GB0218037A external-priority patent/GB0218037D0/en
Priority claimed from GBGB0220197.8A external-priority patent/GB0220197D0/en
Priority claimed from GBGB0220199.4A external-priority patent/GB0220199D0/en
Priority claimed from GB0225531A external-priority patent/GB0225531D0/en
Priority claimed from GB0225524A external-priority patent/GB0225524D0/en
Priority claimed from GB0230170A external-priority patent/GB0230170D0/en
Priority claimed from GB0230164A external-priority patent/GB0230164D0/en
Priority claimed from GB0230168A external-priority patent/GB0230168D0/en
Priority claimed from GB0305028A external-priority patent/GB0305028D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of IS7601A publication Critical patent/IS7601A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7601A 2002-08-02 2004-12-16 Neisser-bóluefnasamsetningar sem innihalda blönduaf mótefnavökvum IS7601A (is)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0218036A GB0218036D0 (en) 2002-08-02 2002-08-02 Vaccine
GB0218051A GB0218051D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218037A GB0218037D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218035A GB0218035D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GBGB0220197.8A GB0220197D0 (en) 2002-08-30 2002-08-30 Refolding method
GBGB0220199.4A GB0220199D0 (en) 2002-08-30 2002-08-30 Mutant protein and refolding method
GB0225531A GB0225531D0 (en) 2002-11-01 2002-11-01 Vaccine
GB0225524A GB0225524D0 (en) 2002-11-01 2002-11-01 Vaccine composition
GB0230170A GB0230170D0 (en) 2002-12-24 2002-12-24 Vaccine
GB0230164A GB0230164D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0230168A GB0230168D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0305028A GB0305028D0 (en) 2003-03-05 2003-03-05 Vaccine
PCT/EP2003/008571 WO2004014418A2 (en) 2002-08-02 2003-07-31 Neisserial vaccine compositions comprising a combination of antigens

Publications (1)

Publication Number Publication Date
IS7601A true IS7601A (is) 2004-12-16

Family

ID=31722002

Family Applications (3)

Application Number Title Priority Date Filing Date
IS7593A IS7593A (is) 2002-08-02 2004-12-13 Bólusetningasamsetning sem samanstendur af transferrín bindi prótíni og HSF úr gram-neikvæðum bakteríum
IS7601A IS7601A (is) 2002-08-02 2004-12-16 Neisser-bóluefnasamsetningar sem innihalda blönduaf mótefnavökvum
IS7658A IS7658A (is) 2002-08-02 2005-01-20 Bóluefna samsetningar sem samanstanda af fitufásykrum af L2 og/eða L3 ónæmisgerð úr 1gtB mengishnettlu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS7593A IS7593A (is) 2002-08-02 2004-12-13 Bólusetningasamsetning sem samanstendur af transferrín bindi prótíni og HSF úr gram-neikvæðum bakteríum

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS7658A IS7658A (is) 2002-08-02 2005-01-20 Bóluefna samsetningar sem samanstanda af fitufásykrum af L2 og/eða L3 ónæmisgerð úr 1gtB mengishnettlu

Country Status (25)

Country Link
US (9) US20060240045A1 (is)
EP (11) EP2481419A3 (is)
JP (7) JP2006500963A (is)
KR (6) KR20050039839A (is)
CN (2) CN1671413A (is)
AU (6) AU2003250204B8 (is)
CA (4) CA2493092A1 (is)
CO (3) CO5680455A2 (is)
CY (3) CY1114243T1 (is)
DE (2) DE20321889U1 (is)
DK (2) DK2255826T3 (is)
ES (3) ES2408251T3 (is)
HU (1) HUE029200T2 (is)
IL (3) IL165660A0 (is)
IS (3) IS7593A (is)
LU (1) LU92262I2 (is)
MX (3) MXPA05000842A (is)
MY (1) MY149591A (is)
NO (3) NO20050008L (is)
NZ (4) NZ537181A (is)
PL (5) PL399492A1 (is)
PT (2) PT1524993E (is)
SI (2) SI1524993T1 (is)
TW (1) TWI360424B (is)
WO (4) WO2004014419A1 (is)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US10967045B2 (en) * 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
EP1228217B1 (en) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
MXPA01011867A (es) 1999-05-19 2002-05-06 Chiron Spa Composiciones neisseriales de combinacion.
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
PT2275553E (pt) 1999-10-29 2015-09-18 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CN102417537A (zh) * 2000-01-25 2012-04-18 昆士兰大学 包含脑膜炎奈瑟氏球菌表面抗原NhhA的保守区域的蛋白质
AU3947801A (en) * 2000-02-28 2001-09-12 Chiron Spa Hybrid expression of neisserial proteins
CA2416137C (en) * 2000-07-27 2013-01-29 Dan Granoff Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
NZ537181A (en) * 2002-08-02 2007-01-26 Glaxosmithkline Biolog S Vaccine composition comprising transferrin binding protein and Hsf from gram negative bacteria
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US8663656B2 (en) * 2002-10-11 2014-03-04 Novartis Ag Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
NZ546601A (en) 2003-09-19 2010-07-30 Epitopix Llc Compositions comprising at least six isolated metal regulated polypeptides obtainable from campylobacter spp
CN103405761A (zh) 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0323709D0 (en) * 2003-10-09 2003-11-12 Health Prot Agency Modified whole cell,cell extract and omv-based vaccines
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2550927A1 (en) 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
CA2566409C (en) * 2004-05-11 2012-12-04 Liana Juliana Josephine Steeghs Neisseria meningitidis igtb lipo-oligo-saccharides as adjuvant
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
GB0428381D0 (en) * 2004-12-24 2005-02-02 Isis Innovation Vaccine
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
AU2006206234B2 (en) 2005-01-21 2012-01-12 Epitopix, Llc Yersinia spp. polypeptides and methods of use
AU2006208208B2 (en) 2005-01-27 2011-05-19 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
UA95238C2 (uk) 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Імуногенна композиція
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7955817B2 (en) 2005-09-02 2011-06-07 Glaxosmithkline Biologicals S.A. Vaccine protection assay
WO2007028408A1 (en) * 2005-09-05 2007-03-15 Glaxosmithkline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US20110008279A1 (en) * 2005-12-06 2011-01-13 Vega Masignani Methods and Compositions Relating to Adhesins as Adjuvants
KR101367237B1 (ko) 2005-12-22 2014-03-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
BRPI0710210A2 (pt) 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
ATE450271T1 (de) * 2006-06-12 2009-12-15 Glaxosmithkline Biolog Sa Impfstoff
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
NZ580030A (en) 2007-04-03 2012-06-29 Biogenerix Ag Methods of treatment using glycopegylated g-csf
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
EA201391788A1 (ru) 2007-06-26 2014-08-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
EP2185576A4 (en) * 2007-08-02 2011-01-12 Childrens Hosp & Res Ct Oak FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES
JP2010535019A (ja) * 2007-08-02 2010-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム リポオリゴ糖（ｌｏｓ）生合成に関わる遺伝子の有無の決定によるナイセリア属菌株の分子タイピング
MX2010004271A (es) 2007-10-19 2010-05-03 Novartis Ag Formulaciones de vacuna meningococica.
US9579372B2 (en) * 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
HRP20150892T1 (hr) 2008-03-03 2015-09-25 Novartis Ag Spojevi i sastavi kao modulatori tlr-aktivnosti
WO2009158142A1 (en) * 2008-05-30 2009-12-30 The U.S.A., As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
KR101042541B1 (ko) * 2008-07-25 2011-06-17 한국생명공학연구원 외막소체를 생산하는 재조합 ｇ（－） 박테리아 및 이를이용한 다가항원이 실린 외막소체의 제조방법
US20110182981A1 (en) * 2008-08-25 2011-07-28 Peixuan Zhu Gonococcal vaccines
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CN102300585A (zh) * 2008-12-17 2011-12-28 诺华有限公司 包含血红蛋白受体的脑膜炎球菌疫苗
CN101759781B (zh) * 2008-12-25 2013-04-03 上海市第六人民医院 一种细菌表层黏附蛋白及其用途
BRPI0924068A2 (pt) 2008-12-25 2016-07-26 Chemo Sero Therapeut Res Inst vacina recombinante contra coriza infecciosa das aves e processo para preparação da mesma
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
RU2549438C2 (ru) * 2009-03-24 2015-04-27 Новартис Аг Комбинации, включающие сахарид пневмококка серотипа 14
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
EP2429576A1 (fr) * 2009-05-14 2012-03-21 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) et de proteine de neisseria meningitidis
AU2010247252A1 (en) * 2009-05-14 2012-01-12 Sanofi Pasteur Method for admixing the lipopolysaccharide (LPS) of gram-negative bacteria
WO2010130898A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
WO2010134225A1 (ja) * 2009-05-20 2010-11-25 国立大学法人鳥取大学 部分糖鎖エピトープを用いた、病原性ナイセリア属細菌感染の検出方法およびそれら細菌に対するワクチン
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
CA2772103A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
US9201072B2 (en) 2009-09-01 2015-12-01 Aeon Medix Inc. Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same
NZ598654A (en) 2009-09-02 2014-05-30 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) * 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
CA2779839A1 (en) * 2009-11-06 2011-05-12 Children's Hospital & Research Center At Oakland T-cell stimulating protein b and methods of use
EP2512478B1 (en) 2009-12-15 2017-04-19 GlaxoSmithKline Biologicals SA Homogeneous suspension of immunopotentiating compounds and uses thereof
CA2792683A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Neisserial fhbp vaccine composition
BR112012022800A2 (pt) * 2010-03-11 2018-05-15 Glaxosmithkline Biologicals Sa composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
MX2012010793A (es) * 2010-03-29 2013-05-09 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas.
AU2013202310C1 (en) * 2010-03-29 2017-01-05 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
AU2011299025B2 (en) 2010-09-09 2015-07-09 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
AU2011300418B2 (en) * 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
ES2529442T3 (es) * 2010-09-28 2015-02-20 Abera Bioscience Ab Proteína de fusión para la expresión de proteínas secretoras
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
CN103687612B (zh) 2011-07-07 2017-12-15 由卫生福利和体育大臣代表的荷兰王国 无去污剂制备革兰氏阴性细菌外膜泡囊的方法
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
AU2013214105A1 (en) 2012-02-02 2014-07-24 Novartis Ag Promoters for increased protein expression in meningococcus
JP5698693B2 (ja) * 2012-03-13 2015-04-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌特異的抗血清に対する血清殺菌アッセイ
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
US20160120818A1 (en) 2013-02-07 2016-05-05 Glaxosmithline Biological Sa Pharmaceutical compositions comprising vesicles
WO2014138290A1 (en) * 2013-03-05 2014-09-12 Trudeau Institute, Inc. Compositions and methods for treating bacterial infections
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
JP6786394B2 (ja) 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変髄膜炎菌ｆＨｂｐポリペプチド
WO2016091902A1 (en) * 2014-12-09 2016-06-16 Sanofi Pasteur Compositions comprising n. meningitidis proteins
EP3298031B1 (en) 2015-05-18 2020-10-21 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
JP7661008B2 (ja) 2017-01-04 2025-04-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルム関連障害の処置のための抗体断片
CA3049105A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Dnabii vaccines and antibodies with enhanced activity
EP3595445B1 (en) 2017-03-15 2024-09-04 The Research Institute at Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
EP3860718A4 (en) 2018-10-05 2022-08-31 Research Institute at Nationwide Children's Hospital HMGB1 PROTEIN DERIVATIVES FOR BIOFILM REMOVAL
CN112996538B (zh) * 2018-11-06 2025-07-08 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
WO2020168146A1 (en) * 2019-02-14 2020-08-20 University Of Florida Research Foundation, Inc. Honeybee commensal snodgrassella alvi vaccine against pathogenic neisseriaceae
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
GB202203250D0 (en) 2022-03-09 2022-04-20 Glaxosmithkline Biologicals Sa Immunogenic compositions
CN119792505A (zh) * 2023-10-10 2025-04-11 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239746A (en) * 1973-06-30 1980-12-16 Dezso Istvan Bartos Complement fixation test employing reactants in a disposable package
DE2744721A1 (de) 1977-10-05 1979-04-19 Veba Chemie Ag Pulverfoermige ueberzugsmittel und deren anwendung
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4271147A (en) 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US20020146764A1 (en) * 1985-03-28 2002-10-10 Chiron Corporation Expression using fused genes providing for protein product
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3622221A1 (de) * 1986-07-02 1988-01-14 Max Planck Gesellschaft Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
ES2160570T3 (es) 1988-12-16 2001-11-16 Nederlanden Staat Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
WO1992001460A1 (en) 1990-07-16 1992-02-06 The University Of North Carolina Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins
DE4023721A1 (de) 1990-07-26 1992-01-30 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
DE69133334T2 (de) 1990-08-23 2004-05-13 University Of North Carolina At Chapel Hill Transferrin bindende proteine aus neisseria-gonorrhoeae und neisseria-meningitidis
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5371186A (en) 1991-02-11 1994-12-06 Biosynth S.R.L. Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
US5652211A (en) 1991-02-11 1997-07-29 Biosynth S.R.L. Peptides for neutralizing the toxicity of Lipid A
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
DE69227898T2 (de) * 1991-03-14 1999-05-12 Imclone Systems, Inc., New York, N.Y. Rekombinante hybride porinepitope
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
CA2127871A1 (en) 1992-01-13 1993-07-22 Andreas Herman Hogt Crosslinking of rubbers with engineering plastics
CA2129899C (en) 1992-02-11 2011-01-04 James J. Mond Dual carrier immunogenic construct
FR2692592B1 (fr) * 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
CZ282235B6 (cs) 1992-06-25 1997-06-11 Smithkline Beecham Biologicals (S.A.) Očkovací prostředek, jeho použití k výrobě vakcíny, způsob léčby patogenních infekcí tímto prostředkem a způsob jeho výroby
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
ATE226831T1 (de) 1993-05-18 2002-11-15 Univ Ohio State Res Found Impfstoff gegen mittelohrentzündung
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6361779B1 (en) 1993-11-08 2002-03-26 Aventis Pasteur Limited Transferrin receptor genes
US6358727B1 (en) 1993-11-08 2002-03-19 Aventis Pasteur Limited Haemophilus transferrin receptor genes
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6287574B1 (en) * 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US6007838A (en) 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
WO1996040928A1 (en) 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
KR19990045763A (ko) * 1995-09-18 1999-06-25 유나이티드 스테이트 아미 메디칼 리서치 머티어리얼커맨드 (유에스에이엠알엠씨) 비공유결합성으로 착염화된 다가의 프로테오좀 서브-유니트 백신의 개선된 제조 방법
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6440701B1 (en) 1996-03-08 2002-08-27 Aventis Pasteur Limited Transferrin receptor genes of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
EP0912608B1 (en) 1996-05-01 2006-04-19 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
PT942983E (pt) 1996-10-31 2007-02-28 Human Genome Sciences Inc Antigénios e vacinas de streptococcus pneumoniae
BR9809914A (pt) 1997-06-03 2001-09-18 Connaught Lab Genes de moracella receptores de lactoferrina
JP2001510031A (ja) 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物
AU4773697A (en) 1997-07-31 1999-02-22 Wilo Gmbh Latent heat storage device for use in a vehicle
IL134436A0 (en) 1997-08-15 2001-04-30 Univ Utrecht Neisseria lactoferrin binding protein
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
SG152917A1 (en) * 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
ATE461709T1 (de) 1998-04-07 2010-04-15 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
GB9809683D0 (en) 1998-05-06 1998-07-01 Smithkline Beecham Biolog Novel compounds
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9811260D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel compounds
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
ES2274627T3 (es) 1998-06-03 2007-05-16 Glaxosmithkline Biologicals S.A. Proteinas y genes de moraxella catarrhalis, antigenos, anticuerpos y usos.
GB9812163D0 (en) 1998-06-05 1998-08-05 Smithkline Beecham Biolog Novel compounds
GB9812440D0 (en) 1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds
GB9814902D0 (en) 1998-07-10 1998-09-09 Univ Nottingham Screening of neisserial vaccine candidates against pathogenic neisseria
US6951652B2 (en) 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
GB9818004D0 (en) * 1998-08-18 1998-10-14 Smithkline Beecham Biolog Novel compounds
GB9820003D0 (en) 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
GB9820002D0 (en) 1998-09-14 1998-11-04 Smithkline Beecham Biolog Novel compounds
WO2000022430A2 (en) * 1998-10-09 2000-04-20 Chiron Corporation Neisseria genomic sequences and methods of their use
EP1123398B1 (en) 1998-10-16 2005-08-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Molecular pathogenicide mediated plant disease resistance
EP1123403A1 (en) * 1998-10-22 2001-08-16 The University Of Montana OMP85 PROTEINS OF $i(NEISSERIA GONORRHOEAE) AND $i(NEISSERIA MENINGITIDIS), COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF
US6610306B2 (en) * 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
US20030215469A1 (en) * 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
DK1127137T4 (da) 1998-11-03 2014-02-10 Nederlanden Staat LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier
MXPA01011047A (es) * 1999-04-30 2003-10-14 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
EP1228217B1 (en) * 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
MXPA01011867A (es) 1999-05-19 2002-05-06 Chiron Spa Composiciones neisseriales de combinacion.
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
EP1218512A2 (en) 1999-06-18 2002-07-03 Elitra Pharmaceuticals, Inc. Nucleotide sequences of moraxella catarrhalis genome
GB2351515B (en) 1999-06-29 2002-09-11 Pandrol Ltd Adjustable railway rail fastening assembly and methods for use therewith
GB9918038D0 (en) 1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds
GB9917977D0 (en) 1999-07-30 1999-09-29 Smithkline Beecham Biolog Novel compounds
GB9918302D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Novel compounds
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9918208D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Novel compounds
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
DE60044005D1 (de) 1999-11-29 2010-04-22 Novartis Vaccines & Diagnostic 85 kDa Antigen von Neisseria
MXPA02006962A (es) * 2000-01-17 2002-12-13 Chiron Spa Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b.
CN102417537A (zh) 2000-01-25 2012-04-18 昆士兰大学 包含脑膜炎奈瑟氏球菌表面抗原NhhA的保守区域的蛋白质
AU3947801A (en) * 2000-02-28 2001-09-12 Chiron Spa Hybrid expression of neisserial proteins
GB0007432D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
CA2416137C (en) 2000-07-27 2013-01-29 Dan Granoff Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
BR0211494A (pt) * 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4522699B2 (ja) * 2001-10-03 2010-08-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化されたＭｅｎｉｎｇｏｃｏｃｃｕｓ組成物
NZ537181A (en) * 2002-08-02 2007-01-26 Glaxosmithkline Biolog S Vaccine composition comprising transferrin binding protein and Hsf from gram negative bacteria
US8663656B2 (en) * 2002-10-11 2014-03-04 Novartis Ag Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0315021D0 (en) * 2003-06-26 2003-07-30 Chiron Srl Immunogenic gonococcal compositions
CN103405761A (zh) * 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409748D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
AU2007263531B2 (en) * 2006-06-29 2012-03-15 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis

Also Published As

Publication number Publication date
TWI360424B (en) 2012-03-21
JP2006500963A (ja) 2006-01-12
PL216662B1 (pl) 2014-04-30
PL399492A1 (pl) 2012-11-19
MXPA05001349A (es) 2005-04-28
PL220107B1 (pl) 2015-08-31
KR20110036642A (ko) 2011-04-07
CN1674933B (zh) 2012-09-26
US20060057160A1 (en) 2006-03-16
US20110033500A1 (en) 2011-02-10
AU2003260357B2 (en) 2009-10-29
EP2258386A2 (en) 2010-12-08
KR101139976B1 (ko) 2012-05-08
NZ537181A (en) 2007-01-26
DK1524993T3 (da) 2013-06-03
JP2006506467A (ja) 2006-02-23
CO5680456A2 (es) 2006-09-29
EP2255826A3 (en) 2012-03-28
CO5680454A2 (es) 2006-09-29
MXPA05001265A (es) 2005-04-28
JP5409986B2 (ja) 2014-02-05
JP2006505628A (ja) 2006-02-16
AU2003250204A1 (en) 2004-02-25
EP1524991A1 (en) 2005-04-27
CY1114243T1 (el) 2015-12-09
DK2255826T3 (en) 2016-06-20
KR20080078082A (ko) 2008-08-26
CA2489030A1 (en) 2004-02-19
IS7658A (is) 2005-01-20
EP1961427A2 (en) 2008-08-27
NO20050010L (no) 2005-02-09
NZ587398A (en) 2012-03-30
WO2004014417A3 (en) 2004-07-22
AU2003253375B2 (en) 2009-07-02
NZ574530A (en) 2010-12-24
IL165660A0 (en) 2006-01-15
IS7593A (is) 2004-12-13
KR101237329B1 (ko) 2013-02-28
EP2258387A2 (en) 2010-12-08
US7838014B2 (en) 2010-11-23
KR20050042143A (ko) 2005-05-04
TW200408406A (en) 2004-06-01
ES2408251T3 (es) 2013-06-19
EP2258384A3 (en) 2011-12-28
JP2011051997A (ja) 2011-03-17
WO2004014417A2 (en) 2004-02-19
US20160082097A1 (en) 2016-03-24
PT1524993E (pt) 2013-06-12
DE20321890U1 (de) 2012-03-12
NO20050421L (no) 2005-03-30
CY2013036I1 (el) 2015-12-09
JP2006500962A (ja) 2006-01-12
JP2011142916A (ja) 2011-07-28
EP1524993A2 (en) 2005-04-27
US20120064119A1 (en) 2012-03-15
AU2003269864A1 (en) 2004-02-25
AU2008202479A1 (en) 2008-06-26
CY1117643T1 (el) 2017-04-26
EP2481419A2 (en) 2012-08-01
KR20050028051A (ko) 2005-03-21
AU2003250204B8 (en) 2008-07-10
ES2575014T3 (es) 2016-06-23
IL166433A (en) 2011-08-31
US8221770B2 (en) 2012-07-17
CO5680455A2 (es) 2006-09-29
PL399214A1 (pl) 2012-11-19
CA2493124A1 (en) 2004-02-19
WO2004015099A3 (en) 2004-04-22
KR20050039839A (ko) 2005-04-29
HK1077014A1 (en) 2006-02-03
WO2004014418A3 (en) 2004-07-22
EP1961427A3 (en) 2009-11-04
AU2003260357A1 (en) 2004-02-25
LU92262I2 (fr) 2013-09-30
KR101239242B1 (ko) 2013-03-11
ES2537737T3 (es) 2015-06-11
PL375407A1 (en) 2005-11-28
CA2493977A1 (en) 2004-02-19
MXPA05000842A (es) 2005-04-28
EP2258384A2 (en) 2010-12-08
US20060240045A1 (en) 2006-10-26
EP2258387A3 (en) 2011-10-19
PL375382A1 (en) 2005-11-28
EP2258385A2 (en) 2010-12-08
CN1674933A (zh) 2005-09-28
US20060034854A1 (en) 2006-02-16
CN1671413A (zh) 2005-09-21
CA2493092A1 (en) 2004-02-19
EP2258386A3 (en) 2011-11-02
AU2008202479C1 (en) 2014-01-16
WO2004015099A2 (en) 2004-02-19
JP2012107036A (ja) 2012-06-07
EP2258385A3 (en) 2012-01-18
DE20321889U1 (de) 2012-03-12
AU2003250204B2 (en) 2008-06-19
WO2004014419A1 (en) 2004-02-19
NZ537904A (en) 2008-03-28
HUE029200T2 (en) 2017-03-28
US20120064120A1 (en) 2012-03-15
EP1524990A2 (en) 2005-04-27
EP2481419A3 (en) 2013-04-10
US20120027800A1 (en) 2012-02-02
EP1524993B1 (en) 2013-03-06
KR101140033B1 (ko) 2012-05-07
EP1524992B1 (en) 2015-03-04
IL166433A0 (en) 2006-01-15
CA2493124C (en) 2014-04-29
PT2255826E (pt) 2016-06-08
KR20120036996A (ko) 2012-04-18
IL213264A0 (en) 2011-07-31
CY2013036I2 (el) 2015-12-09
US20060051379A1 (en) 2006-03-09
SI2255826T1 (sl) 2016-07-29
WO2004014418A2 (en) 2004-02-19
AU2008255270A1 (en) 2009-01-08
SI1524993T1 (sl) 2013-07-31
NO20050008L (no) 2005-04-28
EP2255826B1 (en) 2016-04-13
JP4740738B2 (ja) 2011-08-03
MY149591A (en) 2013-09-13
EP1524992A2 (en) 2005-04-27
AU2008202479B2 (en) 2011-09-22
JP5414651B2 (ja) 2014-02-12
PL375408A1 (en) 2005-11-28
AU2003253375A1 (en) 2004-02-25
JP5789203B2 (ja) 2015-10-07
EP2255826A2 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
IS7601A (is) Neisser-bóluefnasamsetningar sem innihalda blönduaf mótefnavökvum
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
DE602004028262D1 (de) B. pertussis antigene und ihre verwendung bei der vakzinierung
ATE333500T1 (de) Virus des porzinen reproduktiven und respiratorischen syndroms und dessen verwendung
PT1542732E (pt) Proteínas de fusão de mycobacterium tuberculosis
ATE269104T1 (de) Salmonella impfstoff, der keinen antikörper gegen flagellin oder gegen flagella induziert
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2002077648A3 (en) Pathogenic and commensal vaccine antigens
GB0409559D0 (en) Polypeptide
ATE401341T1 (de) Vakzine enthaltend omp85 proteine von neisseria gonorrhoeae und neisseria meningitidis
BR0313121A (pt) Composição imunogênica, vacina, métodos de tratamento ou prevenção de doença neisserial, de preparação da composição imunogênica, de preparação da vacina, de preparação de uma imunoglobina para uso na prevenção ou tratamento de infecção neisserial, e de tratamento ou prevenção de infecção neisserial, usos da vacina e da preparação farmacêutica, cepa neisserial geneticamente engenheirada, imunoglobina, e, composição farmacêutica
WO2005007691A3 (en) East coast fever vaccine based on ctl-specific schizont antigens
WO2005030802A3 (en) Antigens for an east coast fever vaccine